135 related articles for article (PubMed ID: 11983081)
1. Design, production, and characterization of recombinant neocarzinostatin apoprotein in Escherichia coli.
Nozaki S; Tomioka Y; Hishinuma T; Inoue M; Nagumo Y; Tsuruta LR; Hayashi K; Matsumoto T; Kato Y; Ishiwata S; Itoh K; Suzuki T; Hirama M; Mizugaki M
J Biochem; 2002 May; 131(5):729-38. PubMed ID: 11983081
[TBL] [Abstract][Full Text] [Related]
2. Preparation of neocarzinostatin apoprotein mutants and the randomized library on the chromophore-binding cavity.
Tomioka Y; Kisara S; Yoshizawa S; Ozawa M; Suzuki N; Yamaguchi H; Hishinuma T; Mizugaki M; Goto J
Biol Pharm Bull; 2006 May; 29(5):1010-4. PubMed ID: 16651736
[TBL] [Abstract][Full Text] [Related]
3. Reinvestigation of the proteolytic activity of neocarzinostatin.
Heyd B; Lerat G; Adjadj E; Minard P; Desmadril M
J Bacteriol; 2000 Apr; 182(7):1812-8. PubMed ID: 10714984
[TBL] [Abstract][Full Text] [Related]
4. Neocarzinostatin: selective tryptophan oxidation and neocarzinostatin-chromophore binding to apo-neocarzinostatin.
Edo K; Saito K; Matsuda Y; Akiyama-Murai Y; Mizugaki M; Koide Y; Ishida N
Chem Pharm Bull (Tokyo); 1991 Jan; 39(1):170-6. PubMed ID: 1828722
[TBL] [Abstract][Full Text] [Related]
5. Solution structure of a novel chromoprotein derived from apo-neocarzinostatin and a synthetic chromophore.
Urbaniak MD; Muskett FW; Finucane MD; Caddick S; Woolfson DN
Biochemistry; 2002 Oct; 41(39):11731-9. PubMed ID: 12269815
[TBL] [Abstract][Full Text] [Related]
6. Key interactions in the immunoglobulin-like structure of apo-neocarzinostatin: evidence from nuclear magnetic resonance relaxation data and molecular dynamics simulations.
Izadi-Pruneyre N; Quiniou E ; Blouquit Y; Perez J; Minard P; Desmadril M; Mispelter J; Adjadj E
Protein Sci; 2001 Nov; 10(11):2228-40. PubMed ID: 11604530
[TBL] [Abstract][Full Text] [Related]
7. An antitumor polypeptide antibiotic neocarzinostatin: the mode of apo-protein--chromophore interaction.
Edo K; Saito K; Akiyama-Murai Y; Mizugaki M; Koide Y; Ishida N
J Antibiot (Tokyo); 1988 Apr; 41(4):554-62. PubMed ID: 2967272
[TBL] [Abstract][Full Text] [Related]
8. Sequential 1H NMR assignment of the complex of aponeocarzinostatin with ethidium bromide and investigation of protein-drug interactions in the chromophore binding site.
Mohanty S; Sieker LC; Drobny GP
Biochemistry; 1994 Sep; 33(35):10579-90. PubMed ID: 8075058
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional solution structure of apo-neocarzinostatin.
Gao X
J Mol Biol; 1992 May; 225(1):125-35. PubMed ID: 1533878
[TBL] [Abstract][Full Text] [Related]
10. Synthetic ligands for apo-neocarzinostatin.
Caddick S; Muskett FW; Stoneman RG; Woolfson DN
J Am Chem Soc; 2006 Apr; 128(13):4204-5. PubMed ID: 16568976
[TBL] [Abstract][Full Text] [Related]
11. In vitro evolution of the binding specificity of neocarzinostatin, an enediyne-binding chromoprotein.
Heyd B; Pecorari F; Collinet B; Adjadj E; Desmadril M; Minard P
Biochemistry; 2003 May; 42(19):5674-83. PubMed ID: 12741824
[TBL] [Abstract][Full Text] [Related]
12. Neocarzinostatin chromophore. Assignment of spectral properties and structural requirements for binding to DNA.
Napier MA; Goldberg IH
Mol Pharmacol; 1983 Mar; 23(2):500-10. PubMed ID: 6220205
[TBL] [Abstract][Full Text] [Related]
13. Is association of labile enediyne chromophore a mutually assured protection for carrier protein?
Kandaswamy J; Hariharan P; Kumar TK; Yu C; Lu TJ; Chin DH
Anal Biochem; 2008 Oct; 381(1):18-26. PubMed ID: 18601891
[TBL] [Abstract][Full Text] [Related]
14. Rational design of a supra C-1027: kinetically stabilized analogue of the antitumor enediyne chromoprotein.
Usuki T; Inoue M; Hirama M; Tanaka T
J Am Chem Soc; 2004 Mar; 126(10):3022-3. PubMed ID: 15012111
[TBL] [Abstract][Full Text] [Related]
15. Characterization of secondary structure of neocarzinostatin apoprotein.
Saito K; Sato Y; Edo K; Akiyama-Murai Y; Koide Y; Ishida N; Mizugaki M
Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):3078-82. PubMed ID: 2534360
[TBL] [Abstract][Full Text] [Related]
16. Induced formation of a DNA bulge structure by a molecular wedge ligand-postactivated neocarzinostatin chromophore.
Gao X; Stassinopoulos A; Ji J; Kwon Y; Bare S; Goldberg IH
Biochemistry; 2002 Apr; 41(16):5131-43. PubMed ID: 11955061
[TBL] [Abstract][Full Text] [Related]
17. The intrinsic fluorescence of apo-obelin and apo-aequorin and use of its quenching to characterize coelenterazine binding.
Eremeeva EV; Markova SV; Westphal AH; Visser AJ; van Berkel WJ; Vysotski ES
FEBS Lett; 2009 Jun; 583(12):1939-44. PubMed ID: 19426732
[TBL] [Abstract][Full Text] [Related]
18. Construction of a genetically engineered chimeric apoprotein consisting of sequences derived from lidamycin and neocarzinostatin.
Jiang W; Shang B; Li L; Zhang S; Zhen Y
Anticancer Drugs; 2016 Jan; 27(1):24-8. PubMed ID: 26457548
[TBL] [Abstract][Full Text] [Related]
19. The proteolytic specificity of the natural enediyne-containing chromoproteins is unique to each chromoprotein.
Zein N; Reiss P; Bernatowicz M; Bolgar M
Chem Biol; 1995 Jul; 2(7):451-5. PubMed ID: 9383447
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of apo-neocarzinostatin at 0.15-nm resolution.
Teplyakov A; Obmolova G; Wilson K; Kuromizu K
Eur J Biochem; 1993 Apr; 213(2):737-41. PubMed ID: 8477746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
